{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:01:21Z","timestamp":1773842481368,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40801-022-00340-4","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T19:03:07Z","timestamp":1671562987000},"page":"177-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States"],"prefix":"10.1007","volume":"10","author":[{"given":"Neelima","family":"Denduluri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet L.","family":"Espirito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle D.","family":"Hackshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuck","family":"Wentworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamy","family":"Recchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winghan J.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"issue":"5","key":"340_CR1","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. https:\/\/doi.org\/10.1093\/jnci\/dju055.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"340_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1413513.","journal-title":"N Engl J Med"},{"issue":"19","key":"340_CR3","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1209124.","journal-title":"N Engl J Med"},{"key":"340_CR4","unstructured":"National Comprehensive Cancer Network. Breast Cancer (Version 6.2020). September 8, 2020. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 3 Oct 2020."},{"key":"340_CR5","unstructured":"US Food and Drug Administration. FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies. December 23, 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available. Accessed 24 June 2020."},{"key":"340_CR6","unstructured":"US Food and Drug Administration. FDA approves neratinib for metastatic HER2-positive breast cancer. February 26, 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neratinib-metastatic-her2-positive-breast-cancer. Accessed 24 June 2020."},{"key":"340_CR7","unstructured":"US Food and Drug Administration. FDA approves tucatinib for patients with HER2-positive metastatic breast cancer. April 20, 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer. Accessed 24 June 2020."},{"key":"340_CR8","unstructured":"The US Oncology Network. https:\/\/www.usoncology.com\/our-company. Accessed 26 Oct 2020."},{"key":"340_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","volume":"109","author":"F Montemurro","year":"2019","unstructured":"Montemurro F, Ellis P, Anton A, et al. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. Eur J Cancer. 2019;109:92\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.022.","journal-title":"Eur J Cancer"},{"issue":"1","key":"340_CR10","doi-asserted-by":"publisher","first-page":"12760","DOI":"10.1038\/s41598-019-49251-5","volume":"9","author":"M Hardy-Werbin","year":"2019","unstructured":"Hardy-Werbin M, Quiroga V, Cirauqui B, et al. Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep. 2019;9(1):12760. https:\/\/doi.org\/10.1038\/s41598-019-49251-5.","journal-title":"Sci Rep"},{"issue":"1","key":"340_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.12809\/hkmj176808","volume":"24","author":"W Yeo","year":"2018","unstructured":"Yeo W, Luk MY, Soong IS, et al. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. Hong Kong Med J. 2018;24(1):56\u201362. https:\/\/doi.org\/10.12809\/hkmj176808.","journal-title":"Hong Kong Med J"},{"issue":"34","key":"340_CR12","doi-asserted-by":"publisher","first-page":"56921","DOI":"10.18632\/oncotarget.18176","volume":"8","author":"P Vici","year":"2017","unstructured":"Vici P, Pizzuti L, Michelotti A, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8(34):56921\u201331. https:\/\/doi.org\/10.18632\/oncotarget.18176.","journal-title":"Oncotarget"},{"issue":"2","key":"340_CR13","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.clbc.2019.09.001","volume":"20","author":"B Conte","year":"2020","unstructured":"Conte B, Fabi A, Poggio F, et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Clin Breast Cancer. 2020;20(2):e181\u20137. https:\/\/doi.org\/10.1016\/j.clbc.2019.09.001.","journal-title":"Clin Breast Cancer"},{"issue":"suppl 10","key":"340_CR14","first-page":"x26","volume":"28","author":"K Matsui","year":"2017","unstructured":"Matsui K, Yoshikawa A, Oyama K, et al. Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab. Ann Oncol. 2017;28(suppl 10):x26\u201334.","journal-title":"Ann Oncol"},{"key":"340_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510","author":"S Modi","year":"2019","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"key":"340_CR16","doi-asserted-by":"publisher","unstructured":"Modi S, Saura C, Yamashita T, et al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer. In: San Antonio Breast Cancer Symposium, December 8\u201311, 2020.\u00a0Cancer Res 2021;81 (4_Supplement): PD3-06. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PD3-06.","DOI":"10.1158\/1538-7445.SABCS20-PD3-06"},{"key":"340_CR17","unstructured":"NERLYNX (neratinib) tablets, for oral use (package insert). February 2020. https:\/\/nerlynx.com\/pdf\/full-prescribing-information.pdf. Accessed 24 June 2020."},{"issue":"15_suppl","key":"340_CR18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1200\/JCO.2019.37.15_suppl.1002","volume":"37","author":"C Saura","year":"2019","unstructured":"Saura C, Oliveira M, Feng Y-H, et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. J Clin Oncol. 2019;37(15_suppl):1002.","journal-title":"J Clin Oncol"},{"issue":"7","key":"340_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2019","unstructured":"Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2019;382(7):597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609.","journal-title":"N Engl J Med"},{"key":"340_CR20","unstructured":"US National Library of Medicine. ClinicalTrials.gov. A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for patients with advanced or metastatic HER2+ breast cancer. June 2, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03975647. Accessed 24 June 2020."},{"key":"340_CR21","doi-asserted-by":"publisher","unstructured":"Cort\u00e9s J, Shahidi J, Lee C, Zhang Y, Verma S. [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and\/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res. 2020;80(4 Suppl):Abstract nr OT1-07-1. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-OT1-07-01.","DOI":"10.1158\/1538-7445.SABCS19-OT1-07-01"},{"issue":"10","key":"340_CR22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606). Ann Oncol. 2020;31(10):1350\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.020.","journal-title":"Ann Oncol"},{"key":"340_CR23","doi-asserted-by":"publisher","unstructured":"Jerusalem G, Park YH, Yamashita T, et al. CNS metastases in HER2-positive metastatic breast cancer treated with trastizimab deruxtecan: DESTINY-Breast01 subgroup analyses. In: Proceedings of the European Society for Molecular Oncology Virtual Congress 2020. Ann Oncol. 2020;31(S2):S63-S4. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.239.","DOI":"10.1016\/j.annonc.2020.03.239"},{"issue":"27","key":"340_CR24","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/jco.20.00147","volume":"38","author":"C Saura","year":"2020","unstructured":"Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138\u201349. https:\/\/doi.org\/10.1200\/jco.20.00147.","journal-title":"J Clin Oncol"},{"key":"340_CR25","unstructured":"KADCYLA (ado-tratuzumab emtansine). Prescribing Information. Genentech, Inc. South San Francisco, CA, USA. May 2019. www.gene.com\/download\/pdf\/kadcyla_prescribing.pdf. Accessed 7 Jan 2019."},{"issue":"4","key":"340_CR26","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s12325-021-01659-0","volume":"38","author":"X Ma","year":"2021","unstructured":"Ma X, Bellomo L, Magee K, et al. Characterization of a real-world response variable and comparison with RECIST-based response rates from clinical trials in advanced\nNSCLC. Adv Ther. 2021;38(4):1843\u201359. https:\/\/doi.org\/10.1007\/s12325-021-01659-0.","journal-title":"Adv Ther"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00340-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00340-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00340-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T16:14:51Z","timestamp":1685549691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00340-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00340-4","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"26 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Daiichi Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N. Denduluri: consulting or advisory role: Daiichi Sankyo; research funding: Amgen, Novartis, Genentech, Eli Lilly, Pfizer, Daiichi Sankyo, and Immunomedics; travel, accommodations, expenses: Daiichi Sankyo and Seattle Genetics. Michelle D. Hackshaw, Tamy Recchia, and Winghan J. Kwong are employees of Daiichi Sankyo. Janet L. Espirito and Chuck Wentworth are employees of Ontada\/McKesson.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The raw data used for this analysis are not publicly available due to privacy or ethical restrictions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by JLE and CW. All authors reviewed and interpreted the results. The first draft of the manuscript was written by JLE, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Institutional review board and compliance\/privacy approval was gained prior to initiation of the retrospective research. Since this project involved the analysis of existing data and records, study information was analyzed in such a manner that research participants could not be directly identified. Patient informed consent was not required due to the nature of the study design. Thus, exemption status and a waiver of informed consent were approved by The US Oncology, Inc. Institutional Review Board. Data were handled in compliance with <i>the Health Insurance Portability and Accountability Act of 1996<\/i> (HIPAA) and the <i>Health Information Technology for Economic and Clinical Health (HITECH) Act<\/i>.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Since this project involved the analysis of existing data and records, study information was analyzed in such a manner that research participants could not be directly identified. Patient informed consent was not required due to the nature of the study design.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}